Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
Recruiting · Not applicable · NCT04248283
Conditions: Urinary Incontinence, Urinary Incontinence,Stress
At a glance
- Research payments reported, 2025
- $121,027
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 167
About the trial
- Sponsor
- Uromedica
- Tested
- Adjustable Continence Therapy for Women (ACT) (device)
- Dates
- Started 2021-01-26; completion 2032-05-31
- Results posted
- Not yet
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Uromedica, Incorporated reported $121,027 in research payments for this study in 2025 (6 payments).
Products named: Act
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Brian Flynn, MD Urology · Aurora, CO
- Lisa M. Parrillo, MD Urology · Meridian, ID
- Michael P. Feloney, M.D. Urology · Omaha, NE
- Susan Macdonald, M.D. Urology · Hershey, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.